Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, randomised, single and repeat dose parallel group Phase I study to evaluate the pharmacokinetics of ST10 at three dosage levels in subjects with iron deficiency (with or without anaemia).

Next Previous
Trial Profile

An open-label, randomised, single and repeat dose parallel group Phase I study to evaluate the pharmacokinetics of ST10 at three dosage levels in subjects with iron deficiency (with or without anaemia).

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ferric maltol (Primary)
  • Indications Iron deficiency anaemia
  • Focus Biomarker; Pharmacokinetics
  • Sponsors Iron Therapeutics

Most Recent Events

  • 20 Oct 2023 According to a Shield Therapeutics media release, abstract has been accepted for poster presentation presenting post-hoc analysis from this study at the National Association of Nurse Practitioners in Women's Health 26th Annual Women's Healthcare Conference taking place 29 Oct - 1 Nov in San Diego, California. by Dr Michael Cody M.D.
  • 12 Apr 2016 Results published in the European Journal of Drug Metabolism and Pharmacokinetics
  • 27 Sep 2014 Status changed from recruiting to completed as reported by EudraCT record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top